Overview

Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.

Status:
NOT_YET_RECRUITING

Trial end date:
2034-03-01

Target enrollment:

Participant gender:

Summary

Patients with unfavorable intermediate-risk prostate cancer will be randomized between 6 versus 12 months of hormone therapy with radiation therapy. Patients may choose to receive hypofractionated radiation therapy or hypofractionated radiation therapy with high-dose rate brachytherapy. Hypofractionated radiation therapy refers to radiation therapy given fewer treatments, however higher doses per treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Charles LeMoyne Hospital

Treatments:

luprolide acetate gel depot
Radiotherapy